Sonus' EchoGen enhances prostate visualisation
This article was originally published in Clinica
Sonus Pharmaceuticals' imaging agent, EchoGen (dodecafluoropentane), successfully identified 15% of cancerous prostates otherwise diagnosed as normal in a clinical trial at Albany Medical College, New York. The fluorocarbon-based contrast agent also sufficiently improved visualisation in another 15% of 40 men with signs of prostate cancer to suggest a potential benefit from the routine use of EchoGen in prostate disease diagnosis, says Sonus. All men were examined with conventional endorectal grey scale and colour Doppler ultrasound imaging.